Novo Nordisk

Working together since 2013

Novo Nordisk logo 250pxw

Our partnership with Novo Nordisk, Kymab's first, was establihsed in 2013, three years after our formation. 

Kymab granted Novo Nordisk a non-exclusive licence to our proprietary Kymouse™ human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK™ and Kymouse HL™ transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates.

Visit the Novo Nordisk website

Our Kymouse™ platform can deliver the finest novel therapeutic antibodies

Learn more